Condition: Healthy · Sponsor: Spyre Therapeutics, Inc.
This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
This description comes directly from the study's public registry record.
Medical Director, Clinical Development · 617-651-5940 · Spyre_SPY002-072-101@spyre.com
Always discuss trial participation with your own doctor first.
| Spyre Site 2 | Cypress, California, United States | Not Yet Recruiting |
| Spyre Site 1 | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06622070